BioSpace News Archive

CRANBURY, N.J., Feb. 26, 2020 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that John F. Crowley, Chairman and Chief Executive Officer, will present at the Cowen & Company 40th Annual Health Care Conference in Boston, MA on Tuesday, March 3, 2020 at 8:40 a.m. ET. A live audio webcast of the presentation can also be accessed via the Investors section of the Amicus Therapeutics corporate website at http://ir.amicusrx.com/events-and-presentations , and will be ar

2019 revenues nearly doubled to more than $1.1 billion Exceeded improved 2019 guidance 2020 guidance reflects investment in strategic priorities Webcast today, February 26, 2020, at 11:30 a.m. Eastern Time

Feb. 26, 2020 12:00 UTC Triplet Therapeutics to Present at Cowen 40 th Annual Health Care Conference CAMBRIDGE, Mass.--( BUSINESS WIRE )-- Triplet Therapeutics, Inc. , a biotechnology company harnessing new insights from human genetics to develop transformative treatments for repeat expansion disorders, today announced that Nessan Bermingham, Ph.D., Triplet’s co-founder, president and chief executive officer, will present at the Cowen and Company 40 th Annual Health Care Confere

Feb. 26, 2020 12:00 UTC CAMBRIDGE, Mass.--( BUSINESS WIRE )-- Acceleron Pharma Inc. (Nasdaq:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta superfamily therapeutics intended to treat serious and rare diseases, today announced that senior management will participate in two upcoming healthcare investor conferences. Conference Presentation Details: Event: Cowen & Co. 40th Annual Health Care Conference Date/Time: Monday, Ma

MIT Technology Review’s “10 Breakthrough Technologies List of 2020” named Kebotix, a technology platform company for new chemicals and materials, as a key player in the field of AI-designed molecules.

Feb. 26, 2020 12:00 UTC Two of three dose cohorts in Phase 2 CMV vaccine (mRNA-1647) dose-confirmation study completed enrollment; third and final cohort rapidly enrolling Up to $2 billion to invest, including cash and investments, financing proceeds and potentially available grants; reiterates guidance that net cash used in operating activities and for purchases of property and equipment is expected to total between $490 million and $510 million in 2020 CAMBRIDGE, Ma

Two out of the first five patients dosed with IFX-1 achieved complete remission Dose escalation warranted by pharmacodynamic analysis and approved by relevant authorities for a total enrollment of 18 patients in 3 dose cohorts InflaRx to present initial data at the SVB Leerink Global Healthcare Conference today at 9:00 am EST (3:00 pm CET). JENA, Germany, Feb. 26, 2020 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory t

-- First inhaled mRNA therapeutic remains on track to report results from its ongoing multiple-ascending dose (MAD) portion of Phase 1/2 clinical trial in the third quarter of 2020 -- LEXINGTON, Mass., Feb. 26, 2020 (GLOBE NEWSWIRE) -- Translate Bio, Inc. (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction, today announced that the U.S. Food and Drug A

- Clinical data readouts expected throughout 2020 for rilonacept, mavrilimumab, KPL-716 and KPL-404 - - Year-end 2019 cash reserves of $233 million - HAMILTON, Bermuda, Feb. 26, 2020 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients with significant unmet medical need, today reported fourth quarter and full-year 2019 financial resu

Feb. 26, 2020 12:30 UTC 60 subjects enrolled in AXA1665-002 Top-line data expected in mid-2020 IND submission for overt hepatic encephalopathy and initiation of potential registrational Phase 2b/3 clinical trial planned for second half of 2020 CAMBRIDGE, Mass.--( BUSINESS WIRE )-- Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company focused on leveraging endogenous metabolic modulators (EMMs) to pioneer a new approach for treating complex d